Evidence map›Paper›PMID 33287111›Full record

ArticleMolecules (Basel, Switzerland)2020

Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy.

Lingzhi Zhang, Qiurong Ju, Jinjin Sun, Lei Huang, Shiqi Wu, Shuping Wang, Yin Li, Zhe Guan, Qihua Zhu, Yungen Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lingzhi ZhangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Qiurong JuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Jinjin SunState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Lei HuangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Shiqi WuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Shuping WangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Yin LiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Zhe GuanState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.ORCID 0000-0003-0803-5171
Qihua ZhuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Yungen XuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.

Funding

National Natural Science Foundation of China 81502928Outstanding Scientific and Technological Innovation Team Projects of Jiangsu Province, China 2015Six Talent Peaks Project in Jiangsu Province, China 2017, YY-059
6 · The paper itself

Abstract

Concomitant inhibition of MAPK and PI3K signaling pathways has been recognized as a promising strategy for cancer therapy, which effectively overcomes the drug resistance of MAPK signaling pathway-related inhibitors. Herein, we report the scaffold-hopping generation of a series of 1

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationDrug Resistance, NeoplasmHCT116 CellsHumansMaleMAP Kinase Signaling SystemMiceMice, Inbred BALB CMice, NudePhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPyrimidinesRatsAntineoplastic AgentsPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorspyrimidinePyrimidinescross-talkdual ERK/PI3K inhibitorsERK inhibitorPI3K inhibitor

Identifiers

PMID33287111
PMCPMC7730961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.